Kena C. Miller,Aneel Paulus,Kasyapa Chitta,Asher Alban Akmal Chanan-Khan
申请号：
US15322614
公开号：
US20170128518A1
申请日:
2015.07.01
申请国别(地区):
US
年份:
2017
代理人:
摘要：
This document provides methods and materials involved in identifying mammals having blood cancer (e.g., myelomas or lymphomas, including WM, MCL, and DLBCL) that is resistant to treatment with a proteasome inhibitor such as bortezomib (e.g., VELCADE®) as well as methods and materials involved in treating mammals having a blood cancer resistant to a proteasome inhibitor such as bortezomib (e.g., VELCADE®). For example, methods and materials for using the expression level of PSMB9/β1i nucleic acid to identify a mammal as having a blood cancer (e.g., myeloma or lymphoma, such as WM, MCL, or DLBCL) that is resistant to treatment with a proteasome inhibitor such as bortezomib (e.g., VELCADE®) are provided.
